BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2007

View Archived Issues

Recent RTI patent discloses novel therapeutic agents for irritable bowel syndrome

Read More

New agents for endocrine-related disorders imparted in recent patent literature

Read More

Recent patents disclose novel agents for obesity and disorders of lipid and bone metabolism

Read More

Studies reveal efficacy of fluticasone furoate nasal spray in allergic rhinitis

Read More

New trial evaluates topiramate and almotriptan for the treatment of medication overuse headache

Read More

Atorvastatin to be tested in new clinical trial for systemic lupus erythematosus

Read More

Vandetanib begins new phase III trial with pemetrexed for NSCLC

Read More

Javelin signs commercial supply agreement for Dyloject

Read More

Samaritan to market Elaprase in Greece and Cyprus

Read More

Second phase I trial of NGX-426 for chronic pain

Read More

DEBIO-9902 SR implant studied in phase II trial for Alzheimer's

Read More

BiPar Series B financing to support PARP inhibitor development

Read More

Roche and Kosan advance second-generation epothilone into phase II

Read More

Inex eyes close of Tekmira spin-out

Read More

Oral salmon calcitonin begins phase III study in osteoporosis

Read More

Vaccinex and Teva collaborate on VX-15

Read More

Paclitaxel poliglumex active, well tolerated in androgen-independent prostate cancer

Read More

MAP's Unit Dose Budesonide meets endpoints in phase II pediatric asthma trial

Read More

DMXAA increases efficacy of docetaxel in hormone-refractory prostate cancer

Read More

Par returns difimicin marketing rights to Optimer

Read More

Abiraterone active in androgen-independent, castration refractory prostate cancers

Read More

Maturation inhibitor PA-040 begins phase I study

Read More

CYT-500 enters clinic for hormone-refractory prostate cancer

Read More

Identification of ecallantide, an engineered, potent and selective inhibitor of plasma kallikrein

Read More

Humira approved for Crohn's disease

Read More

Cellular and molecular targets in tumor microenvironment considered for chemoprevention

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing